Step Pharma
Step Pharma is the world leader in the discovery and development of inhibitors of CTPS1 (cytidine triphosphate synthase 1) for the treatment of cancer and autoimmune diseases. Step Pharma’s lead program dencatistat (STP938) is a first in class, potent, selective, oral inhibitor of CTPS1 with demonstrated anti-tumor activity. Dencatistat entered clinical development in 2022 in a PhI/II study for the treatment of relapsed and refractory T-cell and B-cell lymphoma. More recently a solid tumour study was started focused on ovarian cancer using the concept of synthetic lethality and biomarker selection of patients. This can ultimately be viewed as a tumour agnostic approach with ovarian cancer being the PoC indication and future plans to expand into other tumour types such as NSCLC with high prevalence of the biomarker.
7-day free trial · no credit card
Verified contacts
10
available on Kipplo
LinkedIn employees
16
1 to 10 range
Open roles
—
no listings
Distinct roles
8
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 10 verified contacts at Step Pharma
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
10 contacts with verified email or phone · masked until revealed.
- AP
Andy Parker
President and Chief Executive Officer · Other
EmailPhone - MH
Maureen Higgins
VP, Head of Clinical Operations · Other
EmailPhone
Showing 2 of 10 verified contacts
Top roles at Step Pharma
8 distinct titles indexed · top 8 shown.
- 2cfo
- 2office manager
- 1()
- 1auxiliar farmacéutico
- 1chief development officer (cdo)
- 1president and chief executive officer
- 1vp, head of clinical operations
- 1è è ()
Sign up to unlock all 10 contacts at Step Pharma
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 10 verified contacts at Step Pharma
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.